NCT02482454View on ClinicalTrials.gov

Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

July 31, 2030

Study Completion Date

July 31, 2033

Conditions
Cholangiocarcinoma
Interventions
PROCEDURE

Radiofrequency ablation

Radiofrequency ablation is performed percutaneously under CT/US guidance

BIOLOGICAL

Cytokine-induced killer cells

The patients received autologous cytokine-induced killer cells transfusion one week after RFA treatment.

Trial Locations (1)

Unknown

The First People's Hospital of Changzhou, Changzhou

All Listed Sponsors
lead

The First People's Hospital of Changzhou

OTHER

NCT02482454 - Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma | Biotech Hunter | Biotech Hunter